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ABSTRACT  
Objective: Extending or controlling the release of highly water soluble drugs from matrix tablets is always a challenge. The research attempt was 
aimed to explore the embedment technique for the development of extended release (ER) matrix tablets of highly water soluble drugs by taking 
Diltiazem HCl as a model drug.  
Methods: The matrix tablets were developed through embedding the drug in the polymer matrix followed by compression using hydroxypropyl 
methylcellulose (HPMC) K 4000, Eudragit RS PO as drug release-retarding polymers. Matrix tablets from the optimized formulations (F5 & F11) 
were also prepared by wet granulation method for comparing the efficiency of both the techniques for controlling the drug release. 
Results: The results of the dissolution studies indicated that the drug release could be controlled only up to 16 h with HPMC K 4000 alone 
(formulation F5), but upon incorporation of Eudragit RS PO, the drug release was extended up to 24 h (formulation F11). The matrix tablets from 
the same formulations, F5 and F11, prepared by wet granulation technique showed the drug release only up to 12 h and 20 h respectively. The drug 
release from these formulations followed first–order kinetics. The mechanism was found to be almost Higuchi’s diffusion along with some 
anomalous transport (non–Fickian diffusion).  
Conclusion: The embedding technique was found to be promising for the development of ER matrix tablets of highly water soluble drugs with 
lesser quantities of polymers. 
Keywords: Embedment, Extended drug release, Water soluble drugs, Wet granulation. 
 
INTRODUCTION 
Controlled drug delivery technology is fast growing because of its 
many potential advantages like minimum fluctuations in plasma drug 
concentration and a reduced frequency of dosing when compared to 
the conventional dosage forms. Many newer technologies are also 
emerging for designing controlling drug delivery systems with 
improved efficiency and embedment [1] is one such novel technique. 
The release rate retarding material or polymer is the major 
component in these systems and its concentration influences the 
release rate of the drug. Oral controlled release systems are highly 
acceptable and can be obtained by employing different techniques [2] 
like prodrugs, ion exchange resins, buffered tablets, microspheres, 
floated tablets, film coating, osmotic pumps and matrix tablets. Matrix 
tablets are more familiar as they are easy to prepare and having more 
industrial feasibility and hence matrix tablets of Diltiazem HCl are 
selected for the present research work. Matrix tablets are the simple 
and economical design and wet granulation is the common and most 
successful approach used to prepare them. However, development of 
controlled release matrix tablets for highly water-soluble drugs is 
always a challenge [3, 4] and requires large quantities of polymer 
especially if the release has to be controlled up to 24 h. 
The present research work was aimed to explore the novel 
embedment technique for its efficiency when compared to the wet 
granulation in obtaining extended release (ER) matrix systems for 
highly water soluble drugs. So, in the present work, diltiazem HCl 
was selected as a model drug because of its good absorption along 
the entire gastrointestinal tract and its short half–life, 3.0–4.5 h [5], 
that favor the design of controlled release formulation. Extensive 
research was published on diltiazem HCl ER formulations, some of 
them are, sustained-release diltiazem matrix tablets using 
hydrophilic gum blends by direct compression [6]; 
The main objective of the present research work was to develop ER 
matrix tablets of diltiazem HCl for once–a–day dosing using a 
combination of a hydrophilic and a hydrophobic polymer viz. are 
HPMC K 4000 and Eudragit RS PO by embedding technique; 
preparing the tablets for the optimized formulations by wet 
granulation; and comparing the drug release profiles of the tablets 
obtained from both the techniques. 
extended release 
matrix tablets of diltiazem using natural gums by wet granulation 
technique [7]; diltiazem HCl ER tablets by melt granulation [8]. All 
these previous work commonly reported that the drug to polymer 
ratio of 1:3 to 1:4 was required to get the desired control release of 
the diltiazem HCl from the matrix tablets prepared by conventional 
wet granulation and direct compression techniques. 
MATERIALS AND METHODS 
Materials 
Diltiazem HCl, HPMC K 4000, Eudragit RS PO were obtained from 
Capricorn Pharma, Hyderabad. Lactose, Magnesium Stearate and 
Talc were purchased from Sd Fine Chem, Mumbai. All the 
ingredients used were of analytical grade. 
Methods 
Drug-excipients compatibility 
Fourier transforms infrared spectroscopy (FT-IR) 
The physicochemical compatibility between diltiazem HCl and 
polymers (HPMC K 4000 and Eudragit RS PO) used in the research 
was carried out by subjecting to IR spectral studies using Perkin 
Fourier Transform infrared Spectrophotometer, Shelton, USA. The 
samples were prepared by mixing the 400 mg of the drug with the 
maximum amounts of polymers (175 mg of HPMC K 4000 and 50 mg 
of Eudragit RS PO) used in the preparation of the tablets [9]. These 
samples were scanned under diffuse reflectance mold and plotted 
the graph by the KBr pellet method and spectra were recorded in the 
wavelength region between 4000 cm-1to 400 cm-1. The spectra 
obtained for the pure drug was compared with that of the physical 
mixtures of the drug with polymers. 
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Differential scanning calorimetry (DSC) 
The thermal behavior of the drug alone (diltiazem HCl) and with 
polymers (HPMC K 4000 and Eudragit RSPO) was analyzed by using 
DSC instrument. The drug and its physical mixture with polymers 
were weighed, crimped in aluminum pans and analyzed at a 
scanning temperature range from 50 to 400oC at the heating rate of 
10o
 
 C/min in nitrogen atmosphere [10]. 
Table 1: Formulae for Diltiazem HCl ER matrix tablets of batch 1 (F1–F6) 
S. No. Ingredient Quantity in mg per one tablet 
F1 F2 F3 F4 F5 F6 
1 Diltiazem HCl 400 400 400 400 400 400 
2 HPMC K 4000 50 75 100 125 150 175 
3 Starch 160 135 110 85 60 35 
4 Magnesium stearate 5 5 5 5 5 5 
5 Talc 5 5 5 5 5 5 
 Total weight 620 620 620 620 620 620 
 
Table 2: Formulae for diltiazem HCl ER matrix tablets of batch 2 (F7–F11) 
S. No. Ingredient Quantity in mg per one tablet 
F7 F8 F9 F10 F11 
1 Diltiazem HCl 400 400 400 400 400 
2 HPMC K 4000 150 150 150 150 150 
3 Eudragit RS PO 10 20 30 40 50 
4 Starch 50 40 30 20 10 
5 Magnesium stearate 5 5 5 5 5 
6 Talc 5 5 5 5 5 
 Total weight 620 620 620 620 620 
 
Preparation of diltiazem HCl ER matrix tablets by embedding 
technique 
Diltiazem HCl ER matrix tablets were prepared as of two batches. In 
the first batch formulations, only HPMC K 4000 was incorporated in 
the increasing quantities as shown in the table 1. The second batch 
formulations contain the fixed quantity of HPMC K 4000 (at which 
the maximum controlling of the drug release was observed) and 
increasing quantities of Eudragit RS PO (as shown in the table 2). 
In this technique, tablets were prepared in two successive steps. 
Step 1: Embedment of the drug in polymer matrix 
Weighed quantities of polymer(s) (only HPMC K 4000 for first batch 
and both HPMC K 4000 & Eudragit RS PO for the second batch), 
according to the formulae shown in tables 1 and 2, were transferred 
into a porcelain dish. To this, ethanol was added slowly with 
continuous trituration until a smooth paste was formed. Then the 
weighed quantities of the drug and starch were incorporated into 
the smooth paste of the polymers by levigation technique. Then the 
obtained semisolid mass was spread over the walls of the porcelain 
dish and was dried in a hot air oven until complete drying. Then the 
dried material was scrapped and passed through a sieve #20. The 
granules obtained were studied for their densities, flow properties 
and compressibility prior to the compression. 
Step 2: Compression 
The above-obtained drug entrapped polymer matrix granules were 
properly lubricated with previously screened (through #100) and 
weighed quantities of magnesium stearate and talc. Then the blend 
was subjected to compression by using the 12 stage rotary tablet 
press to obtain the tablets weighing 620 mg each. Obtained tablets 
were stored properly until further use. 
Matrix tablets from the formulations F5 and F11 were also prepared 
by wet granulation technique by using the same sieve (#20) that is 
used in the embedment technique.  
Characterization of granules 
Prepared granules of all formulations were evaluated for their 
micromeritic properties viz. are bulk density, tapped density, Car’s 
index, Hausner’s ratio and angle of repose to ensure their suitability 
to compression. 
Evaluation of ER matrix tablets 
All the prepared tablets were evaluated for the following 
parameters.  
Thickness 
The thickness and diameter of the tablets were measured by using 
Vernier calipers. 
Weight variation 
Twenty tablets were randomly selected from each batch, 
individually weighed; the average weight and standard deviation of 
20 tablets were calculated. The % weight variation was calculated by 
using following formula: 
% weight variation= [(Average weight-individual weight)/average 
weight] x100 
Hardness 
Hardness or tablet crushing strength (Fc
Friability 
); the force required to 
break a tablet in a diametric compression was measured using a 
Pfizer tablet hardness tester. 
Friability of tablets was determined using Roche friabilator (United 
States Pharmacopoeia). A pre-weighed sample of tablets was placed 
in the friabilator and subjected to 100 revolutions at 25 rpm. Tablets 
were dedusted using a soft muslin cloth and reweighed.  
% friability = [(Initial weight–Final weight)/Initial weight] × 100. 
Tensile strength 
Tensile strength of tablets was calculated using the following 
formula [11]: 
T= 2Fc/πd t. Fc-
Wetting time 
crushing strength, d-diameter, t-thickness of the 
tablet. 
A piece of paper folded twice was kept in a Petri dish containing 6 ml 
of purified water. A tablet having a small amount of Rosaline dye 
powder on the upper surface was placed on the tissue paper. The 
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time required to develop a red color on the upper surface of the 
tablet was recorded as the wetting time [12]. 
Swelling index 
The tablet was weighed (wo) and placed in the dissolution medium 
and maintained at 37 oC. At predetermined time intervals the tablet 
was withdrawn and blotted to remove excess water and weighed 
(wt) until constant weight is obtained [13]. The percentage of 
swelling index was calculated with the formulae:  
Swelling index= 100× (Wt–Wo)/Wt 
Where, Wt = final weight of the tablet, Wo 
Dissolution rate of Diltiazem HCl from all formulations was 
performed using DISSO 800, an 8 stage dissolution rate test 
apparatus with a paddle stirrer. The dissolution fluid was 900 ml 
phosphate buffer pH 5.8, the paddle was rotated at 100rpm & the 
temperature was maintained at 37±0.5
= initial weight of the tablet. 
Estimation of drug content 
5 tablets were taken and grinded to powder. 100 mg of the drug 
equivalent tablet powder was taken and dissolved in distilled water 
and the volume was made up to 100 ml with distilled water in a 100 
ml volumetric flask. Then the solution was filtered to remove any 
insoluble matter and the filtrate was taken, made suitable dilutions 
and the absorbance was measured in the UV–Visible 
spectrophotometer at 237 nm. From the obtained absorbance, the 
drug content was calculated by using the standard calibration curve. 
Drug release studies 
o
Kinetic studies 
C. Samples of dissolution 
medium (5 ml) were withdrawn through a filter using cotton as the 
filter media at different time intervals, suitably diluted and assayed 
for Diltiazem HCl by measuring absorbance at 237 nm. These studies 
were conducted in triplicate. 
The kinetics of drug release was studied by subjecting the obtained 
dissolution data to zero–order and first–order models to know the 
kinetic order of drug release; and Higuchi’s and Korsemeyer–Peppas 
models to know the mechanism of drug release. 
Statistical analysis 
The results obtained from the drug release studies were subjected to 
Analysis of Variance (ANOVA) to check whether the influence of the 
nature of the polymer and the type of method on the drug release 
was significant or not [14]. 
RESULTS AND DISCUSSION 
FT–IR studies 
The characteristic peaks of the pure Diltiazem HCl viz. at 3431.07, 
3056.11, 1680.13 and 1218.39 corresponding to the characteristic 
functional groups N-H of 2 °-amide group, C-H (aromatic), C=O of 
ketone group and C-O of ether group respectively were observed 
with the spectra of pure Diltiazem HCl as well as the physical 
mixtures. This indicated that the drug had no incompatibility with 
the polymers employed. 
 
 
Fig. 1: FT–IR spectra of pure Diltiazem HCl 
 
 
Fig. 2: FT–IR spectra of physical mixture of Diltiazem HCl and HPMC K4000 
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Fig. 3: FT–IR spectra of physical mixture of Diltiazem HCl and Eudragit RS PO 
 
 




Fig. 5: DSC spectra of (a) pure Diltiazem HCl and (b) physical mixture of Diltiazem HCl with HPMC K 4000 and Eudragit RS PO 
 
Srikar et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 12, 270-276 
274 
DSC studies 
The thermograms of both pure drug (fig. 5a) and its physical mixture 
with both the polymers (fig. 5b) showed the endotherm (of melting 
point) corresponding to the drug at 216.1oC and 217.4o
The bulk density before and after a suitable tapping procedure was 
varied for all the formulations in the range of 0.51 to 0.58 g/ml to 
0.58 to 0.67 g/ml respectively. The change in the bulk densities, 
before and after tapping, indicated that the granules were having 
good compressibility and packageability. The results of the 
flowability studies (angle of repose 14.8 to 18.9; Car’s index 7.58 to 
12.58; and Hausner’s ratio 1.10 to 1.20) indicated that the granules 
of all the formulations were having good to excellent flowability. 
These studies combinely indicated that the granules of all 
formulations and of embedment technique along with wet 
granulation were efficient for the further processing, i.e. 
compression.  
C 
respectively. This indicated that the drug was compatible with the 
polymers as there was no significant difference in the melting point 
Evaluation studies for Pre-compressed blend 
General physical evaluation studies of the prepared matrix 
tablets 
The tablets were subjected to different physical evaluation tests. The 
weight variation of all the formulations was within the range of 2.38 
to 3.68% and this indicated that the tablets of all the formulations 
were having a uniform weight which in turn indicated that the 
tablets might not have any problem of drug content uniformity. The 
results of hardness (5.2–6.1 Kg/cm2), tensile strength (5.97x10-6 to 
6.74 x10-6 N/m2
 
) and friability (0.52–0.86%) indicated that the 
tablets were sufficiently hard enough to resist the external pressures 
during handling, packaging and transportation. This might be 
attributed to excellent cohesive characteristics of the complex high 
molecular hydroxyl propyl methyl cellulose (HPMC K 4000) and its 
effective utilization by this embedment technique. The results of the 
assay were within the acceptable limits and indicated that uniform 
drug distribution could be achieved by this technique. 
Table 3: Results of assay, wetting time and swelling index tests of Diltiazem HCl ER matrix tablets 
S. No. Formulation Results (average±std. deviation*) 
Assay (%) Wetting time (min) Swelling index (%) 
1 F1 98.31±1.21 16±0.14 27.6±0.2 
2 F2 98.58±1.13 17±0.15 38.8±0.3 
3 F3 99.28±1.51 19±0.13 49.6±0.5 
4 F4 99.12±0.98 23±0.20 59.5±0.4 
5 F5 98.65±1.05 26±0.16 70.3±0.6 
6 F6 99.55±1.32 26±0.19 74.7±0.7 
7 F5 97.82±1.52 WG 20±0.18 68.9±0.5 
8 F7 98.23±1.11 25±0.21 72.5±0.5 
9 F8 97.66±0.87 27±0.16 71.8±0.6 
10 F9 99.21±1.34 26±0.14 73.2±0.5 
11 F10 97.08±1.21 28±0.03 75.3±0.7 
12 F11 98.79±1.18 28±0.21 76.4±0.4 
13 F11 97.38±1.37 WG 25±0.19 74.3±0.7 
* n = 3 
 
Wetting time 
The results of wetting time (shown in table 5 and 6) indicated that the 
tablets were compact enough for the controlled penetration of 
dissolution medium which might control the drug dissolution rate. From 
the results, it was inferred that upon increasing the concentration of  
 
 
All values were expressed as mean±SD (n=3) 
Fig. 6: Drug release profiles of Diltiazem HCl ER matrix tablets 
of all formulations 
 
Swelling index 
The results of swelling index (shown in table 5 and 6) indicated that 
upon increasing the concentration of HPMC K 4000, the swelling 
index was also increased, i.e. more amount of the water was 
absorbed by the polymer and a complex gel barrier was formed, 
which might control the dissolution rate. 
 
 
All values were expressed as mean±SD (n=3) 
Fig. 7: Difference in drug release profiles between the same 
formulations of Diltiazem HCl ER matrix tablets prepared from 
embedment (F5 & F11) and wet granulation (F5wg & F11wg) 
 
HPMC K 4000, the wetting time was also increased which might be 
attributed to the increased control of the dissolution rate.  
Drug release studies 
The results of the drug release studies of formulation F1 to F6 (shown 
in fig. 6 and table 4) indicated that upon increasing the amount of 
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HPMC K 4000, the dissolution rate constant was decreased, i.e. more 
controlled release was achieved with increasing amount of HPMC K 
4000, from F1 to F5, and the drug release was controlled up to 16 h 
(98.12%). This might be attributed to the higher amounts of HPMC K 
4000 develop more complex gel barrier upon contact with the 
dissolution fluids. Even though F6 contains more amount of polymer 
than in the F5, the drug release was controlled for only 16 h (97.68%) 
and the dissolution rate was also not further decreased significantly. 
This indicated that upon an increase in the amount of HPMC K 4000 
more than 150 mg, the drug release could not be controlled further 
and also signified the necessity of incorporating a water insoluble 
polymer to get further control in drug release. 
The results of drug release studies of formulations F7 to F11 (shown 
in fig. 6 and table 4) indicated that upon increasing the 
concentration of eudragit polymer, the dissolution rate was 
controlled and the drug release was controlled up to 24 h with 
formulations F10 and F11. This might be attributed to the, 
hydrophobic nature of the polymer, increased with the 
concentration, which can resist the penetration of dissolution 
medium and further diffusion of the drug. Even though formulation 
F10 controlled the drug release for 24 h, it has failed to pass the 
dissolution criteria according to USP and NF. So, the formulation F11 
was developed and it showed the dissolution criteria according to 
the compendial requirements. 
The drug release from all these formulations followed first–order 
kinetics (shown in fig. 6 and table 4) and the order of kinetics was not 
affected by the concentration of Eudragit RS PO. The drug release 
mechanism was found to be almost Higuchi’s diffusion along with some 
anomalous transport (non–Fickian diffusion) which was evidenced by 
the regression coefficient of Higuchi’s plots and Peppas ‘n’ values. 
The matrix tablets for the selected formulations F5 and F11, which 
had shown best results in their batches prepared by embedment 
technique, were also prepared by traditional wet granulation 
technique (named as F5WG and F11WG) and subjected to similar drug 
release studies. The results (shown in fig. 6) indicated that the drug 
release rates from the tablets of F5WG and F11WG
In the wet granulation technique, the drug was mixed with the 
polymer in dry powder form, but in the embedment technique, the 
polymers were and made into semisolid form by the little quantity of 
solvents, so that the drug was effectively incorporated into the 
flexible polymer matrix. This made effective utilization of the 
polymers and better control of drug release. Results of ANOVA 
(shown in table 5) also indicated that the influence of the type of 
method on the drug release was significant which means 
embedment technique showed significant control in drug release 
over wet granulation technique. 
 were found to be 
more than those of the tablets of F5 and F11, which signified that the 
embedment technique was more effective than wet granulation in 
controlling the drug release of a highly water-soluble drug like 
Diltiazem HCl. This might be attributed to the effective entrapment 
of the drug in the polymer matrix in the embedment technique.  
The works on the Diltiazem HCl extended-release tablets reported 
in the previous works by the other authors by wet granulation 
showed to control the release of 90 mg of the drug, 300 mg of 
single or combination of polymers (Locust bean gum, Karaya gum) 
with drug i.e. at 1:1 was required to control the drug release up to 
12 h [6], similar amounts of polymers (Tamarind xyloglucan gum, 
Gellan gum and Sodium CMC) were required to control the release 
up to 24 h [7]. Upon comparing the results of the present work and 
the previous works by the other authors, it was evident that 
embedment technique was more effective than wet granulation in 
controlling the drug release of highly water soluble drugs and 
requires lesser quantities of polymers which would be further 
advantageous in developing the extended release formulations for 
large dosed drugs. 
 
Table 4: Dissolution kinetics of Diltiazem HCl ER matrix tablets of all formulations 
S. No. Formulation Regression coefficient (R2 Dissolution rate constant (hr) value -1 Peppas exponential constant (n) ) 
Zero–order First–order Higuchi’s 
1 F1 0.995 0.826 0.949 0.631 0.845 
2 F2 0.988 0.914 0.960 0.472 0.795 
3 F3 0.974 0.920 0.961 0.322 0.776 
4 F4 0.975 0.872 0.970 0.302 0.775 
5 F5 0.666 0.969 0.986 0.206 0.561 
6 F6 0.703 0.963 0.986 0.203 0.599 
7 F5 0.794 WG 0.972 0.981 0.256 0.645 
8 F7 0.709 0.987 0.989 0.200 0.578 
9 F8 0.616 0.990 0.975 0.177 0.560 
10 F9 0.687 0.992 0.985 0.150 0.591 
11 F10 0.609 0.995 0.982 0.136 0.568 
12 F11 0.662 0.996 0.982 0.114 0.599 
13 F11 0.726 WG 0.988 0.979 0.157 0.620 
 
Table 5: Results of ANOVA for the effect of polymer and the method on the drug release rate constant of Diltiazem HCl ER matrix tablets 
Source Sum of squares Degrees of freedom Mean sum of squares F value p–value prob>F 
Model 0.011 2 5.641 x 10 460.51 -3 0.0329 
A–polymer 9.120 x 10 1 -3 9.120 x 10 744.51 -3 0.0233 
B–method 2.162 x 10 1 -3 2.162 x 10 176.51 -3 0.0478 
Residual 1.225 x 10 1 -5 1.225 x 10  -5  
Total  3    
The Model F-value of 460.51 implies the model is significant, There is only a 3.29% chance that a "Model F-Value" this large could occur due to 
noise, Values of "Prob>F" less than 0.0500 indicate model terms are significant, In this case A, B are significant model terms, Values greater than 
0.1000 indicate the model terms are not significant 
 
CONCLUSION 
The results of the drug release studies on the prepared matrix 
tablets revealed that the embedment technique was more 
effective for the efficient incorporation of drug in the polymer 
matrix than wet granulation technique for the preparation of ER 
formulations so that lesser quantities of polymers are sufficient 
to get the desired control release. Therefore, it can be concluded 
that even for the high water soluble drugs like Diltiazem HCl, 
extended or controlled release matrix tablets can be effectively 
prepared with less quantity of polymers by the embedment 
technique. 
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